{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:35:10Z","timestamp":1793115310196,"version":"4.5.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Vaccine-induced immune thrombocytopenia and thrombosis (VITT) and VITT-like syndromes are emerging causes of severe thrombocytopenia and thrombosis associated with immunoglobulin G (IgG) antibodies targeting platelet factor 4 (PF4). These syndromes are characterized by more frequent and severe thrombosis than heparin-induced thrombocytopenia (HIT), which is typically caused by antibodies targeting heparin-modified PF4 (anti-PF4\/H). In this study, we compared the intrinsic prothrombotic properties of IgG anti-PF4 and anti-PF4\/H to identify mechanisms that may contribute to the severity of VITT and VITT-like syndromes. Using the monoclonal IgG1 antibodies 1E12 (anti-PF4) and 5B9 (anti-PF4\/H), we showed that IgG anti-PF4 exhibited an increased propensity to induce the formation of fibrin-rich platelet\u2013leukocytes aggregates in a microfluidic model of whole-blood (WB) thrombosis. This phenomenon was related to a strong potentiation of thrombin generation in plasma by 1E12, but not by 5B9, and occurred only in the presence of platelets and coagulation factors V and XI. We also demonstrated a substantially faster and stronger ability of 1E12, compared with 5B9, to activate platelets using the serotonin release assay and confirmed these findings using human VITT and HIT samples. Furthermore, 1E12 was more likely than 5B9 to induce procoagulant platelets (CD62P+\/phosphatidylserine+) in platelet-rich plasma (PRP) and to produce procoagulant microvesicles in WB and PRP. In conclusion, platelets are activated faster and exhibit more procoagulant activity in response to anti-PF4 than anti-PF4\/H, which may contribute to the severity of VITT and VITT-like syndromes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020237","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:09:51Z","timestamp":1788386991000},"page":"7048-7057","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Anti-PF4 antibodies trigger a faster and stronger platelet procoagulant response than anti-heparin\/PF4 antibodies"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5005-0819","authenticated-orcid":false,"given":"Johanna","family":"Augros","sequence":"first","affiliation":[{"name":"1INSERM UMR 1327 ISCHEMIA \"Membrane Signalling and Inflammation in Reperfusion Injuries\", University of Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6861-1551","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Rollin","sequence":"additional","affiliation":[{"name":"1INSERM UMR 1327 ISCHEMIA \"Membrane Signalling and Inflammation in Reperfusion Injuries\", University of Tours, Tours, France"},{"name":"2Department of Hematology and Hemostasis, University Hospital Center of Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Benzakine","sequence":"additional","affiliation":[{"name":"1INSERM UMR 1327 ISCHEMIA \"Membrane Signalling and Inflammation in Reperfusion Injuries\", University of Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Archer","sequence":"additional","affiliation":[{"name":"1INSERM UMR 1327 ISCHEMIA \"Membrane Signalling and Inflammation in Reperfusion Injuries\", University of Tours, Tours, France"},{"name":"2Department of Hematology and Hemostasis, University Hospital Center of Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4718-126X","authenticated-orcid":false,"given":"Sandra","family":"Billy","sequence":"additional","affiliation":[{"name":"1INSERM UMR 1327 ISCHEMIA \"Membrane Signalling and Inflammation in Reperfusion Injuries\", University of Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Dupont","sequence":"additional","affiliation":[{"name":"3INSERM U1011-European Genomic Institute for Diabetez, Institut Pasteur de Lille, Universit\u00e9 de Lille, Centre Hospitalier Universitaire de Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Daniel","sequence":"additional","affiliation":[{"name":"3INSERM U1011-European Genomic Institute for Diabetez, Institut Pasteur de Lille, Universit\u00e9 de Lille, Centre Hospitalier Universitaire de Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1250-6063","authenticated-orcid":false,"given":"Yves","family":"Gruel","sequence":"additional","affiliation":[{"name":"1INSERM UMR 1327 ISCHEMIA \"Membrane Signalling and Inflammation in Reperfusion Injuries\", University of Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3420-8438","authenticated-orcid":false,"given":"Claire","family":"Pouplard","sequence":"additional","affiliation":[{"name":"1INSERM UMR 1327 ISCHEMIA \"Membrane Signalling and Inflammation in Reperfusion Injuries\", University of Tours, Tours, France"},{"name":"2Department of Hematology and Hemostasis, University Hospital Center of Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7106-4365","authenticated-orcid":false,"given":"Caroline","family":"Vayne","sequence":"additional","affiliation":[{"name":"1INSERM UMR 1327 ISCHEMIA \"Membrane Signalling and Inflammation in Reperfusion Injuries\", University of Tours, Tours, France"},{"name":"2Department of Hematology and Hemostasis, University Hospital Center of Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"22","key":"2026102711114731700_bib1","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"2026102711114731700_bib2","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1056\/NEJMc2106383","article-title":"PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia","volume":"385","author":"Vayne","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"2026102711114731700_bib3","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical features of vaccine-induced immune thrombocytopenia and thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"2026102711114731700_bib4","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1182\/blood.2021014684","article-title":"Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis","volume":"139","author":"Craven","year":"2022","journal-title":"Blood"},{"issue":"26","key":"2026102711114731700_bib5","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood.2023022136","article-title":"Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure","volume":"142","author":"Sch\u00f6nborn","year":"2023","journal-title":"Blood"},{"issue":"18","key":"2026102711114731700_bib6","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1056\/NEJMc2310644","article-title":"More on adenovirus-associated thrombocytopenia, thrombosis, and VITT-like antibodies","volume":"389","author":"Warkentin","year":"2023","journal-title":"Reply. N Engl J Med"},{"issue":"7","key":"2026102711114731700_bib7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMc2413301","article-title":"Maternal anti-PF4 antibodies as cause of neonatal stroke","volume":"392","author":"H\u00e4usler","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"2026102711114731700_bib8","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMoa2415930","article-title":"VITT-like monoclonal gammopathy of thrombotic significance","volume":"392","author":"Wang","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"2026102711114731700_bib9","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1182\/blood.V97.10.3300","article-title":"Induction of monocyte tissue factor expression by antibodies to heparin\u2013platelet factor 4 complexes developed in heparin-induced thrombocytopenia","volume":"97","author":"Pouplard","year":"2001","journal-title":"Blood"},{"issue":"10","key":"2026102711114731700_bib10","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1111\/jth.13786","article-title":"5B9, a monoclonal antiplatelet factor 4\/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies","volume":"15","author":"Kizlik-Masson","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2026102711114731700_bib11","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1055\/s-0040-1712957","article-title":"Comparative analysis of a French prospective series of 144 patients with heparin-induced thrombocytopenia (FRIGTIH) and the literature","volume":"120","author":"Gruel","year":"2020","journal-title":"Thromb Haemost"},{"issue":"7873","key":"2026102711114731700_bib12","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-021-03744-4","article-title":"Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia","volume":"596","author":"Huynh","year":"2021","journal-title":"Nature"},{"issue":"19","key":"2026102711114731700_bib13","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMc2402592","article-title":"Antibody fingerprints linking adenoviral anti-PF4 disorders","volume":"390","author":"Wang","year":"2024","journal-title":"N Engl J Med"},{"issue":"14","key":"2026102711114731700_bib14","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1182\/blood.2022017696","article-title":"Vaccine-induced immune thrombotic thrombocytopenia","volume":"141","author":"Cines","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2026102711114731700_bib15","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.3324\/haematol.2021.280251","article-title":"The deglycosylated form of 1E12 inhibits platelet activation and prothrombotic effects induced by VITT antibodies","volume":"107","author":"Vayne","year":"2022","journal-title":"Haematologica"},{"issue":"8","key":"2026102711114731700_bib16","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.jtha.2024.05.005","article-title":"The use of 1E12, a monoclonal anti-platelet factor 4 antibody, to improve the diagnosis of vaccine-induced immune thrombotic thrombocytopenia","volume":"22","author":"Vayne","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2026102711114731700_bib17","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3324\/haematol.2021.280366","article-title":"Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy","volume":"107","author":"Greinacher","year":"2022","journal-title":"Haematologica"},{"issue":"3","key":"2026102711114731700_bib18","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1055\/s-0040-1717078","article-title":"Characterization of new monoclonal PF4-specific antibodies as useful tools for studies on typical and autoimmune heparin-induced thrombocytopenia","volume":"121","author":"Vayne","year":"2021","journal-title":"Thromb Haemost"},{"issue":"1","key":"2026102711114731700_bib19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1067\/mlc.2001.115525","article-title":"Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia\/thrombosis","volume":"138","author":"Visentin","year":"2001","journal-title":"J Lab Clin Med"},{"issue":"12","key":"2026102711114731700_bib20","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1182\/bloodadvances.2024015095","article-title":"Cooperative effect between anti-PF4\/H and anti-PF4 antibodies increases cell activation and thrombotic risk in HIT","volume":"9","author":"Billy","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"2026102711114731700_bib21","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/jth.14749","article-title":"Evaluation of functional assays for the diagnosis of heparin induced thrombocytopenia using 5B9, a monoclonal IgG that mimics human antibodies","volume":"18","author":"Vayne","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"15","key":"2026102711114731700_bib23","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1182\/blood-2014-09-594515","article-title":"Increased risk of thrombosis in Fc\u03b3RIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2","volume":"125","author":"Rollin","year":"2015","journal-title":"Blood"},{"issue":"24","key":"2026102711114731700_bib24","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1182\/blood.2024025476","article-title":"Procoagulant platelet activation promotes venous thrombosis","volume":"144","author":"Kaiser","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2026102711114731700_bib25","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s004280050203","article-title":"Pathomorphological aspects of heparin-induced thrombocytopenia II (HIT-II syndrome)","volume":"432","author":"Hermanns","year":"1998","journal-title":"Virchows Arch"},{"issue":"8","key":"2026102711114731700_bib26","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.3324\/haematol.2021.279000","article-title":"Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia","volume":"106","author":"Althaus","year":"2021","journal-title":"Haematologica"},{"issue":"22","key":"2026102711114731700_bib27","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2021013231","article-title":"Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia","volume":"138","author":"Greinacher","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2026102711114731700_bib28","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.jtha.2023.05.001","article-title":"Consensus report on markers to distinguish procoagulant platelets from apoptotic platelets: communication from the Scientific and Standardization Committee of the ISTH","volume":"21","author":"Josefsson","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2026102711114731700_bib29","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1182\/bloodadvances.2024014167","article-title":"Platelet spleen tyrosine kinase is a key regulator of anti-PF4 antibody-induced immunothrombosis","volume":"9","author":"Zlamal","year":"2025","journal-title":"Blood Adv"},{"issue":"9","key":"2026102711114731700_bib30","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/j.1538-7836.2009.03514.x","article-title":"Thrombin generation and heparin-induced thrombocytopenia","volume":"7","author":"Tardy-Poncet","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2026102711114731700_bib31","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1182\/bloodadvances.2022008122","article-title":"Platelet procoagulant membrane dynamics: a key distinction between thrombosis and hemostasis?","volume":"7","author":"Agbani","year":"2023","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026102711114731700_bib32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/ijlh.13866","article-title":"Update on platelet procoagulant mechanisms in health and in bleeding disorders","volume":"44","author":"Bourguignon","year":"2022","journal-title":"Int J Lab Hematol"},{"issue":"26","key":"2026102711114731700_bib33","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1182\/blood-2011-07-368811","article-title":"Polyphosphate is a cofactor for the activation of factor XI by thrombin","volume":"118","author":"Choi","year":"2011","journal-title":"Blood"},{"issue":"26","key":"2026102711114731700_bib34","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1182\/blood-2012-07-444935","article-title":"Inhibition of polyphosphate as a novel strategy for preventing thrombosis and inflammation","volume":"120","author":"Smith","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2026102711114731700_bib35","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.jtha.2025.01.014","article-title":"Structural and functional changes underlying activation of monocytes in heparin-induced thrombocytopenia","volume":"23","author":"Andrianova","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2026102711114731700_bib36","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1038\/s41467-022-32946-1","article-title":"NETosis and thrombosis in vaccine-induced immune thrombotic thrombocytopenia","volume":"13","author":"Leung","year":"2022","journal-title":"Nat Commun"},{"issue":"12","key":"2026102711114731700_bib37","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/bloodadvances.2024014165","article-title":"Endothelial cell activation enhances thromboinflammation in vaccine-induced immune thrombotic thrombocytopenia","volume":"9","author":"Dupuy","year":"2025","journal-title":"Blood Adv"},{"issue":"22","key":"2026102711114731700_bib39","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood.2019000437","article-title":"Cleavage of anti-PF4\/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia","volume":"133","author":"Kizlik-Masson","year":"2019","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/20\/7048\/2595316\/blooda_adv-2026-020237-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/20\/7048\/2595316\/blooda_adv-2026-020237-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:11:59Z","timestamp":1793113919000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/20\/7048\/570725\/Anti-PF4-antibodies-trigger-a-faster-and-stronger"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":37,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026,10,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020237","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,27]]},"published":{"date-parts":[[2026,10,16]]}}}